TL;DR
UCLA has identified a drug, DDL-920, that replicates the effects of physical stroke rehabilitation in mice, marking a potential breakthrough in stroke recovery treatment. Human testing is still pending.
UCLA researchers have announced the development of DDL-920, the first drug shown to fully replicate the brain repair effects of physical stroke rehabilitation in mouse models, marking a significant advance in stroke treatment.
The study, published in Nature Communications, found that DDL-920 excites parvalbumin neurons, which are crucial for generating gamma oscillations linked to neural network coordination and movement recovery after stroke. In mouse models, administration of DDL-920 resulted in substantial improvements in movement control, comparable to those achieved through physical rehabilitation.
Researchers identified that stroke causes disconnection of brain cells, particularly in parvalbumin neurons, leading to impaired gamma oscillations and disrupted neural networks. Physical therapy restores these oscillations, promoting brain network reorganization. The drug DDL-920 was developed to mimic this process by directly stimulating parvalbumin neurons, thereby restoring neural connectivity.
Why It Matters
This discovery could transform stroke recovery by providing a pharmacological alternative or supplement to physical rehabilitation, which often has limited effectiveness due to patients’ inability to sustain intensive therapy. If proven safe and effective in humans, DDL-920 could significantly reduce disability caused by stroke and accelerate recovery timelines.
JBMBHC Rehabilitation Robot Gloves, Finger Exerciser for Stroke Recovery Hand Glove Equipment Hand Function Rehabilitation (Orange Right Hand L)
Rehabilitation Robot Gloves: For people who need to train their hands and fingers, it is an excellent home…
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Stroke remains the leading cause of adult disability worldwide, with limited pharmacological options available for brain repair. Current treatments focus on immediate stroke management, with rehabilitation being the primary method for recovery. Prior to this, no drugs had been shown to replicate the neural plasticity effects of physical therapy. The UCLA study builds on understanding how brain networks reorganize post-stroke, specifically targeting the role of gamma oscillations and parvalbumin neurons in neural connectivity and movement control.
“Our goal is to develop a medicine that produces the effects of rehabilitation, which could be a game-changer for stroke patients unable to sustain intensive therapy.”
— Dr. S. Thomas Carmichael
“DDL-920 specifically excites parvalbumin neurons, restoring gamma oscillations and neural connectivity disrupted by stroke.”
— Varghese John, UCLA researcher
Non-Invasive Brain Stimulation: New Prospects in Cognitive Neurorehabilitation (Special Issues of Neuropsychological Rehabilitation)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It is not yet clear whether DDL-920 will be safe or effective in humans, as the current findings are limited to mouse models. Further studies are needed to evaluate its safety profile and optimal dosage before human trials can begin.
FitBeast Finger Exerciser Set – 5 Resistance Clips for Hand Therapy, Grip Strength & Dexterity – Ideal Finger Strengthener for Rehab, Stroke Recovery, Arthritis, Seniors & Athletes
𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝘃𝗲 𝗥𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗧𝗿𝗮𝗶𝗻𝗶𝗻𝗴: This hand therapy equipment set includes 5 color-coded finger exerciser with resistance levels from 1…
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Next steps include conducting preclinical safety assessments and initiating phase I clinical trials to test DDL-920’s safety in humans. Researchers will also explore dosing protocols and long-term effects.
Make My Brain Great Again Funny Brain Tumor Surgery Recovery T-Shirt
" Make My Brain Great Again Brain " for Brain Tumor Surgery Recovery
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is DDL-920?
DDL-920 is a drug developed by UCLA that stimulates parvalbumin neurons to promote brain network repair after stroke, mimicking physical rehabilitation effects.
When could this drug be available for human use?
It is too early to say; after further safety and efficacy testing in humans, clinical trials would need to be completed before approval and widespread use.
How does DDL-920 work?
The drug excites parvalbumin neurons, restoring gamma oscillations that are essential for neural network coordination and movement recovery post-stroke.
Are there any risks associated with DDL-920?
Risks are currently unknown; comprehensive safety studies are required before human trials.
Could this drug replace physical therapy?
It is not yet clear; initially, DDL-920 may serve as an adjunct to physical rehab or offer an alternative for patients unable to undergo intensive therapy.
